Oramed officer Avi Gabay proposes $93.4K share sale

The proposed sale is pursuant to a Rule 10b5-1 trading plan adopted March 30, 2026.

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. (ORMP) officer Avi Gabay reported a proposed sale of 20,000 common shares, with an aggregate market value of $93,400 and an approximate sale date of October 1, 2026. The sale is pursuant to a Rule 10b5-1 trading plan adopted March 30, 2026. The notice also lists 73,360 shares sold July 1, 2026, for $330,742.20 during the prior three months.

Key Figures

Shares to be sold: 20,000 shares Aggregate market value: $93,400 Shares outstanding: 41,597,354 shares +3 more

6 metrics

Shares to be sold 20,000 shares Proposed sale; approximate sale date October 1, 2026

Aggregate market value $93,400 Proposed sale

Shares outstanding 41,597,354 shares Issuer shares outstanding listed in the notice

Shares issued upon vesting of RSUs 105,030 shares June 18, 2026; no consideration

Shares sold during the past three months 73,360 shares Sale reported for July 1, 2026

Aggregate value of shares sold $330,742.20 Sale reported for July 1, 2026

Key Terms

Rule 144, Rule 10b5-1 trading plan, RSUs, aggregate market value

4 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1 trading plan regulatory

"sold pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

RSUs financial

"shares issued upon vesting of RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

aggregate market value financial

"20,000 | 93400.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORMP shares does Avi Gabay plan to sell?

The notice lists a proposed sale of 20,000 common shares, with an aggregate market value of $93,400 and an approximate sale date of October 1, 2026.

How did Avi Gabay acquire the ORMP shares listed in the notice?

The notice lists 105,030 common shares issued upon vesting of RSUs on June 18, 2026, for no consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 07:44 AM Accepted by SEC EDGAR 10/01/2026 - 07:43 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001777328
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ORAMED PHARMACEUTICALS INC.
SEC File Number	001-35813
Address of Issuer	1185 AVENUE OF THE AMERICAS 3RD FLOOR New York NEW YORK 10036
Phone	646-844-1164
Name of Person for Whose Account the Securities are To Be Sold	Avi Gabay
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	20000	93400.00	41597354	10/01/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/18/2026	Shares issued upon vesting of RSUs	ORAMED PHARMACEUTICALS INC.			105030	06/18/2026	No consideration, shares issued upon vesting of RSUs

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Avi Gabay 1185 AVENUE OF THE AMERICAS 3RD FLOOR New York NY 10036	Common Stock	07/01/2026	73360	330742.20

144: Remarks and Signature

Remarks	The securities are being sold pursuant to a Rule 10b5-1 trading plan adopted on 03/30/2026
Date of Notice	10/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Avi Gabay By: /s/ Netta Cohen Title: Authorized Signatory, Oppenheimer Israel (pursuant to delegation)
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)